Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, gives an update on the results of a Phase I/II dose-escalation study evaluating DS-7300a, a novel antibody-drug conjugate (ADC) directed against B7H3 in patients with advanced solid malignant tumors (NCT04145622). The trial reported activity and tolerability at different dose levels in castrate-resistant prostate cancer (CRPC), squamous cell carcinomas (SCC) of the head and neck, of the lung and of the gastro-esophageal junction. It is known that B7H3 is also expressed across a wide range of tumor types where it is associated with a poor prognosis and poor treatment response to anti-PD-1 therapy. Preliminary results suggest that DS-7300a may be a promising treatment strategy post-chemotherapy and post-immunotherapy in many tumor types. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.